Description of the medicine: Phosphadenum (Phosphadenum)
Adenosine-5'-monophosphoric acid, or adenine 9-b-D-ribofuranoside phosphoric ester.
Synonyms: Adenyl, Adenosine monophosphate, AMP, Adenil, Adenovite, Adenyl, AMP, Cardiomone, Fosfostimol, Monophosaden, Phosaden, Vitamin B8.
Flavourless white crystalline powder. Slightly soluble in water, soluble in 1% sodium bicarbonate solution.
Phosphaden (AMP) can be considered as a fragment of adenosine triphosphoric acid (ATP). AMP is a part of a number of coenzymes that regulate redox processes (See Flavinate, Cobamamide.). Participates in the normalization of porphyrin biosynthesis. It has a vasodilating effect. It has anti-aggregation properties.
Used in the treatment of acute intermittent porphyria and lead poisoning with severe polyneurotic syndrome, chronic obliterating endarteritis, thrombophlebitis, chronic venous insufficiency, venous thrombosis; sometimes with coronary heart disease.
There is evidence of an improvement in the condition of patients with psoriasis in the treatment of phosphadenomas, as well as patients with diabetic retinopathy.
In case of duodenal ulcer, an acceleration of the regression of the ulcer defect and a tendency to normalization of immunological parameters were noted (intramuscularly 1% solution of 5 ml 2 times a day for 10 12 days). No significant effect on secretory and acid-forming functions was noted.
Apply phosphaden orally in tablets (regardless of food intake) and intramuscularly in the form of a disodium salt solution.
In acute porphyria, it is first administered intramuscularly, starting from 0.06 g (3 ml of a 2% solution) 5 times a day, gradually reducing the dose to 0.06 g 2 times a day, and then they switch to taking the drug inside by 0.05 g 2 times a day; take a long time (depending on the condition of the patient).
In diseases of the peripheral vessels, 0.04 g (2 ml of a 2% solution) is prescribed intramuscularly 2 to 3 times a day (2 to 4 weeks), then inside, 0.05 g 2 to 3 times a day.
In chronic coronary heart disease, 0.04 g is administered intramuscularly 3 to 4 times a day for 25 to 30 days, then they are given orally 0.05 g 4 times a day.
For other diseases, it is prescribed orally at 0.025-0.05 g (up to 0.15 g per day) or intramuscularly at 0.02-0.04 g (up to 0.12 g per day) for 2 to 4 weeks.
In ophthalmic practice, phosphaden is used orally at 0.05 g 2 times a day, as well as in the form of retrobulbar injections.
When taking phosphaden inside, nausea, dizziness, tachycardia, allergic reactions may occur; in these cases, reduce the dose or stop further use of the drug.
Method of production: tablets of 0.025 and 0.05 g in a package of 30 pieces or in orange glass jars of 50 pieces; 2% solution for injection (Solutio Phosphadeni 2% PPO injectionibus; pH 6, 7 - 7, 5) in a package of 10 ampoules.
Storage: in a dry (tablet), dark place.